ExSight Ventures, a venture capital firm dedicated to investing in transformative ophthalmology innovations, today announced its investment in RevOpsis Therapeutics, a biotechnology company pioneering next-generation therapies for retinal diseases.

Founded in 2018, RevOpsis Therapeutics is a privately held, next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies. Guided by a team of leading physicians, scientists, and business leaders, we are dedicated to leveraging our proprietary Rev-Mod Platform to develop and commercialize groundbreaking treatments for chronic multifactorial diseases. With a steadfast commitment to responsibly advancing patient care, we aim to usher in a new era of improved disease management and extended disease remission.